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Abstract
One of the beneficial effects of pneumococcal conjugate vaccines (PCVs) has been a
decrease in the incidence of non-invasive infections, such as otitis media (OM) caused by
vaccine serotypes. In this study, we analyzed the epidemiology of pneumococcal OM before
and after PCV13 introduction in 2010. Between 2008 and 2016, the middle ear exudates
from 2653 children under 14 years of age with OM were studied in two Spanish provinces
(Gipuzkoa and Barcelona), and S. pneumoniae was isolated in 235 (8.9%) of cases. The
204 available isolates were serotyped and distributed in three 3-year periods: one before
and two after PCV13 introduction (early and late post-PCV13). A significant decrease in the
rate of OM caused by S. pneumoniae was observed mainly due to a decrease in infections
caused by all PCV13 serotypes, although exceptions were observed including the persis-
tence of serotype 3 in Gipuzkoa and a weak re-emergence of serotype 19F in both regions.
The rate and diversity of non-PCV13 serotypes increased in both regions and an emerging
clone causing OM was detected in each region: serotype 23B ST2372 in Gipuzkoa and
serotype 11A ST838/ST6521 in Barcelona. The introduction of PCV13 has been followed
by a change in the epidemiology of pneumococcal OM, with a decrease in the rate of vac-
cine serotypes accompanied by an increase in the diversity of non-vaccine serotype and the
clonal spreading of different single clones in each region.
Introduction
Acute otitis media (OM) is an important health and economic problem since it is one of the
main reasons for health care center visits, antibiotic prescriptions and pediatric surgical proce-
dures [1–3]. Between 50% and 85% of children will have had one or more episodes of OM
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during their first 3 years of life and 40% six or more during their first 7 years of life [2]. Haemo-
philus influenzae and Streptococcus pneumoniae are the main bacteria responsible for OM.
Moraxella catarrhalis, Streptococcus pyogenes and Staphylococcus aureus are also commonly
found to be causing OM [4–6]. In particular, it is estimated that pneumococcus produces 30–
50% (300 million per year) of all cases of acute OM worldwide [7]. S. pneumoniae can colonize
the human nasopharynx from the first weeks of life reaching colonization rates as high as
89.5% in under-3-year-olds [8]. Once carriage status is established, pneumococcal ascension
through the Eustachian tubes can lead to an initial episode of OM. Recurrent OM episodes are
often associated with polymicrobial infections (S. pneumoniae, H. influenzae and M. catarrha-
lis) and the formation of biofilm which increases the persistence of the infection [9]. Early
pneumococcal OM episodes are caused by serotypes commonly associated with invasive dis-
ease, while recurrences are more often associated with less invasive serotypes which are more
prone to produce mixed infections and biofilm formation [10–12].
The polysaccharide capsule is the most important factor in S. pneumoniae virulence and
invasiveness. Around 97 different capsular types (serotypes) have been described and pneumo-
coccal conjugate vaccines (PCVs) developed to date contain the capsular polysaccharides of a
limited number of serotypes including those most frequently found to be causing invasive
pneumococcal disease (IPD). At present, PCV13 is the conjugate vaccine that covers the most
serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F) licensed in Spain for all ages
(from 6 weeks of age) to prevent pneumococcal meningitis, sepsis, pneumonia and otitis [13].
The introduction of PCVs led to a reduction in IPD as a consequence of a decrease in the inci-
dence of vaccine serotypes [14,15]. Nevertheless, an undesirable increase in IPD caused by
non-vaccine serotypes has also been observed [15–17]. Although the effect of PCVs on OM
has not been as widely studied as that on IPD, a similar pattern has been observed, with a
decrease in OM caused by vaccine serotypes and an increase in OM caused by non-vaccine
serotypes [18–20].
Given the important health and economic problems associated with pneumococcal OM,
more epidemiological studies are necessary to improve our knowledge of the effect of pneumo-
coccal conjugate vaccination on OM. Therefore, we conducted a study on cases of pediatric
pneumococcal OM in children seen at two referral hospitals in different regions in the north
of Spain more than 500 km apart with different vaccination coverage. The main objectives of
this study were to determine and explore changes over time in the pneumococcal serotypes
causing OM throughout the period 2008–2016 (before and after PCV13) and analyze the
impact of PCV13 on OM in these two regions.
Materials and methods
Patients and isolates
The study was conducted between 2008 and 2016 at Donostia University Hospital in San
Sebastian and at Sant Joan de Deu Hospital in Barcelona. The former hospital handles most of
the emergency care and admissions of the pediatric population in the province of Gipuzkoa
(around 95,000 children in 2015), while the latter has an estimated pediatric catchment popu-
lation of 250,000 children <14 years and is a pediatric referral center, which captures around
22% of all pediatric admissions in the region of Catalonia. PCVs were not subsidized by the
corresponding public health systems in Gipuzkoa and Barcelona until 2015 and 2016, respec-
tively, but have been available through private providers since the beginning of the study
period. The vaccine coverage rate in children younger than 2 years was estimated to be about
70% in Gipuzkoa and 55% in Barcelona in the initial part of the study period, based on the
number of vaccine doses sold and published studies [21], rising to coverage rates of>95%
Pneumococcal otitis media in Spain after PCV13
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once PCVs were included on the child immunization schedule by the corresponding public
health systems. In this study, a patient initially vaccinated with PCV7 and then with PCV13
was only considered to have been vaccinated with PCV13.
The study period was divided into three 3-year periods: pre-PCV13 (from 2008 to 2010),
early post-PCV13 (from 2011 to 2013) and late post-PCV13 period (from 2014 to 2016).
The study included all S. pneumoniae isolates cultured from ear discharge swabs of children
aged between 0 and 14 years old diagnosed with OM with spontaneous drainage at the emer-
gency room or hospital wards of either of the participating hospitals. Swab samples were col-
lected as part of routine care by pediatricians at the two hospitals and anonymized before
starting the study. Samples were sent to the Microbiology Departments where they were pro-
cessed by Gram-staining and culture. Pneumococci were identified by their colony morphol-
ogy, the presence of alpha-hemolysis on blood-agar cultures, optochin susceptibility and bile
solubility and were prospectively frozen at -80˚C for further studies. Other bacteria frequently
associated with OM were identified using standard microbiological procedures [11]. Pneumo-
coccal capsular types were determined with multiplex PCR combined with fragment analysis
using automated fluorescent capillary electrophoresis [22] and serotypes confirmed with the
Quellung reaction.
Molecular characterization of pneumococcal isolates
Serotype 11A, 19F and 23B pneumococcal isolates were further characterized by multi-locus
sequence typing following a protocol published elsewhere (https://pubmlst.org/spneumoniae/).
Statistical analyses
Differences in the distribution of serotypes were assessed with the chi-square test or Fisher’s
exact test when appropriate. Trends over time were analyzed with the chi-square test for trend
(GraphPad Instat ver 3.05. La Jolla, CA, USA). A p value of<0.05 was considered statistically
significant. Diversity was assessed by calculation of Simpson’s index (using a tool available at
http://www.comparingpartitions.info/index.php).
Ethical considerations
Publication of the results was approved by the Ethics Committee for Clinical Research of the
Health Area of Gipuzkoa and by the Ethics Committee of Sant Joan de De´u Hospital. All rele-
vant anonymized data are available within the manuscript and its Supporting Information files.
Results
Between 2008 and 2016, a bacterial pathogen was identified in 725 (46.1%) of the 1,571 mid-
dle-ear exudates collected from children with OM aged�14 years old in Gipuzkoa. S. pneumo-
niae accounted for 140 (8.9%) of all OM episodes (Table 1), of which samples were available
for microbiological studies in 116 cases (83%). During the same period in Barcelona, S. pneu-
moniae was identified in 95 (8.8%) of a total of 1,082 middle-ear exudates collected, and sam-
ples were available for further studies in 88 (92.6%) cases. A decrease in the rate of S.
pneumoniae OM was observed between the first and second periods (2008–2010 and 2011–
2013) in Gipuzkoa (p = 0.02) and Barcelona (p<0.001), while no differences were observed
between the second and third periods (2011–2013 and 2014–2016; p = 0.2 in Gipuzkoa and
p = 0.5 in Barcelona). There were no differences between the regions in the rates of S. pneumo-
niae isolated from the middle-ear exudate cultures of children with OM in any of the three
periods (p>0.05 in all cases).
Pneumococcal otitis media in Spain after PCV13
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Pediatric pneumococcal OM was most frequent in children aged 0 to 2 years (57.8% in
Gipuzkoa and 81.8% in Barcelona) (Table 2). First episodes of pneumococcal OM were mainly
seen in 1- (26.7%) and 2-year-olds (19.8%) in Gipuzkoa, while in Barcelona, a higher percent-
age of cases were found in children < 1 year (34.5%) and 1 year old (31%).
Forty (34.5%) children with pneumococcal OM in Gipuzkoa and 51 (58%) in Barcelona
had received the PCV (p<0.001).
Distribution of the serotypes and changes over time
Taking into account all cases in both regions, the introduction of PCV13 was accompanied by
a gradual decrease in the proportion of pneumococcal OM caused by PCV13 serotypes, from
73% in 2008–2010 (pre-PCV13) to 51% in 2011–2013 (early post-PCV13) to 41% in 2014–
2016 (late post-PCV13) (p for trend p = 0.001) (Table 3, Fig 1A and Fig 1C). These decreases
between the same periods were more evident in Barcelona, from 79% to 44% to 24%
(p<0.001) than in Gipuzkoa, where the decrease from 67% to 55% to 52% was less pro-
nounced, not reaching statistical significance (p = 0.48).
Three serotypes, 3, 19A and 19F accounted for 87/204 (42.6%) of all pneumococcal OM in
both regions (Fig 1A and Fig 1C), but the distribution of serotypes was not the same. Specifi-
cally, the percentages of OM attributable to serotypes 19A and 3 were 23.9% and 8% in Barce-
lona while the rates were nearly the opposite in Gipuzkoa: 10.3% and 26.7%, respectively
(p�0.01 for both serotypes). Serotype 19F accounted for 6% of OM cases in Gipuzkoa and for
10.2% of cases in Barcelona (p = 0.30).
In Gipuzkoa, serotypes 19A and 3 were the most prevalent in the pre-PCV13 period but
while the rate of serotype 19A OM declined from 29.2% to 3.8% (p = 0.003) between 2008–
2010 and 2014–2016, the rate of serotype 3 remained stable (20.8% and 26.9%, respectively,
p = 0.78). In Barcelona, serotype 19A was the most prevalent in the pre-PCV13 period and
decreased significantly from 46.4% to 6.1% between 2008–2010 and 2014–2016 (p<0.001),
while the prevalence of serotype 3 did not change significantly (10.7% and 3%, respectively,
p = 0.325). A surprising increase in OM due to serotype 19F was also observed in both regions,
Table 1. Temporal distribution of middle-ear exudate cultures performed and pneumococcal positivity in Gipuzkoa and Barcelona, 2008–2016.
Gipuzkoa Barcelona Total
Years Total
culture
Pneumococcal
positive
Total
culture
Pneumococcal
positive
Total
culture
Pneumococcal
positive
n n % n n % n n %
2008–10 189 24 12.7% 175 32 18.3% 364 56 15.4%
2011–13 681 50 7.3% 360 28 7.8% 1041 78 7.5%
2014–16 701 66 9.4% 547 35 6.4% 1248 101 8.1%
Total 1571 140 8.9% 1082 95 8.8% 2653 235 8.9%
https://doi.org/10.1371/journal.pone.0209048.t001
Table 2. Distribution of pediatric pneumococcal OM episodes in Gipuzkoa and Barcelona by age group. 2008–2016.
Gipuzkoa Barcelona
Age
(years)
2008–2010 2011–2013 2014–2016 Total 2008–2010 2011–2013 2014–2016 Total Total
study
0–2 17 22 28 67 (57.8%) 25 21 26 72 (81.8%) 139 (68.1%)
3–4 3 7 10 20 (17.2%) 1 1 6 8 (9.1%) 28 (13.7%)
5–14 4 11 14 29 (25.0%) 2 5 1 8 (9.1%) 37 (18.1%)
Total 24 40 52 116 28 27 33 88 204
https://doi.org/10.1371/journal.pone.0209048.t002
Pneumococcal otitis media in Spain after PCV13
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from 1.9% in 2008–2010 to 11.8% in 2014–2016, a difference that nearly reached statistical sig-
nificance (p = 0.052).
Contrarily, the rates and diversity of non-PCV13 serotypes causing OM increased over the
years. Between 2008–2010 and 2014–2016, the number of different serotypes responsible for
pneumococcal OM increased from 11 to 24 in Gipuzkoa and from 9 to 13 in Barcelona (Fig 1B
and Fig 1D). Simpson’s index showed that serotype diversity increased non-significantly dur-
ing the study from 0.540 (95% CI 0.363–0.718) to 0.730 (95% CI 0.629–0.830) in Gipuzkoa and
from 0.570 (95% CI 0.369–0.771) to 0.657 (95% CI 0.540–0.773) in Barcelona.
Among non-PCV13 serotypes, a large increase was observed in the rate of one specific sero-
type in each region. In Barcelona, there was a marked increase in serotype 11A OM, from 0%
in 2008–2010 to 45.5% in 2014–2016 (p<0.005), while in Gipuzkoa, OM caused by serotype
23B increased after 2010, this having been the most frequent non-PCV13 serotype since 2011
(16% of all non-PCV13 serotypes). Interestingly, in Barcelona, most 11A OM episodes
occurred in vaccinated children, whereas most cases of 23B infection occurred in unvaccinated
children (Table 4).
Table 3. Number of episodes of pediatric pneumococcal OM in Gipuzkoa and Barcelona by serotype, 2008–2016.
Region Serotype 2008–2010 2011–2013 2014–2016 Total
n % n % n % n %
Gipuzkoa PCV13 16 (66.7%) 22 (55.0%) 27 (51.9%) 65 (56.0%)
non-PCV13 8 (33.3%) 18 (45.0%) 25 (48.1%) 51 (44.0%)
Barcelona PCV13 22 (78.6%) 12 (44.4%) 8 (24.2%) 42 (47.7%)
non-PCV13 6 (21.4%) 15 (55.6%) 25 (75.8%) 46 (52.3%)
Total PCV13 38 (73.1%) 34 (50.7%) 35 (41.2%) 107 (52.5%)
non-PCV13 14 (26.9%) 33 (49.3%) 50 (58.8%) 97 (47.5%)
https://doi.org/10.1371/journal.pone.0209048.t003
Fig 1. Distribution of serotypes causing OM is two Spanish regions. Percentage of PCV13 serotypes (A) and non-
PCV13 serotypes (B) causing OM in each period in Gipuzkoa. Percentage of PCV13 serotypes (C) and non-PCV13
serotypes (D) causing OM in each period in Barcelona.
https://doi.org/10.1371/journal.pone.0209048.g001
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Clonal characterization of serotypes 11A, 19F and 23B
In Gipuzkoa, the number of serotype 19F OM episodes gradually rose from 0 in 2008–2010 to
2 cases in 2011–2013 to 5 cases in 2014–2016. The 2 cases in 2011–2013 and 4 of the 5 cases in
2014–2016 were ST179 isolates (Table 5), while the other case in 2014–2016 was ST5216. The
same trend was observed in Barcelona, with only 1 serotype 19F OM episode in 2008–2010
(ST1545), 3 in 2011–2013 (two ST179, one ST15) and 5 (four ST179, one ST51) in 2014–2016.
Of the 16 serotype 19F cases, 6 occurred in children fully vaccinated with PCV13.
Table 4. Distribution (number) by serotypes and vaccination status of the episodes of pneumococcal OM in Gipuzkoa and Barcelona. 2008–2016.
Gipuzkoa Barcelona
Serotype Vaccinated Non-vaccinated Vaccinated Non-vaccinated
PCV13 2008–
2010
2011–
2013
2014–
2016
2008–
2010
2011–
2013
2014–
2016
Total 2008–
2010
2011–
2013
2014–
2016
2008–
2010
2011–
2013
2014–
2016
Total
1 2 1 3 1 1
3 2 3 5 10 11 31 2 1 1 2 1 7
4 1 1 0
5 1 1 0
6A 0 1 2 3
6B 1 1 0
7F 2 1 1 4 0
9V 1 1 2 0
14 2 2 1 1
18C 1 1 0
19A 2 2 2 5 1 12 7 3 1 6 3 1 21
19F 2 2 2 6 1 1 1 2 4 9
23F 0 0
Total PCV13 2 11 12 14 11 14 64 10 5 2 12 7 6 42
Non-PCV13
11A 1 2 2 4 1 10 2 12 3 17
23B 1 5 4 10 1 1 2
others 1 2 8 5 6 10 32 4 6 9 2 5 1 27
Total non-
PCV13
1 3 11 7 15 15 52 4 9 21 2 6 4 46
https://doi.org/10.1371/journal.pone.0209048.t004
Table 5. Clonal distribution of OM cases caused by S. pneumoniae serotypes 19F, 11A and 23B in Gipuzkoa and Barcelona.
Period Gipuzkoa Barcelona
serotype 19F ST179 serotype 19F ST179
2008–2010 0 0 1 0
2011–2013 2 2 3 2
2014–2016 5 4 5 4
serotype 11A ST838/ST6521 serotype 11A ST838/6521
2008–2010 2 0/1 0 0/0
2011–2013 5 0/1 2 0/1
2014–2016 3 0/2 15 5/9
serotype 23B ST2372 serotype 23B ST2372
2008–2010 0 0 0 0
2011–2013 5 5 2 2
2014–2016 4 4 0 0
https://doi.org/10.1371/journal.pone.0209048.t005
Pneumococcal otitis media in Spain after PCV13
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In Barcelona, a dramatic increase from 0 to 15 cases of serotype 11A OM was also observed
between 2008–2010 and 2014–2016. Of the isolates from the 2 cases in 2011–2013, 1 was iden-
tified as ST6521 and the other as ST62, while the 15 episodes recorded in 2014–2016 were clas-
sified as ST6521 (n = 9), ST838 (n = 5) and ST3687 (n = 1). In Gipuzkoa, the 2 cases of
serotype 11A OM in 2008–2010 were identified as ST6521 and ST62, while the 8 serotype 11A
OM cases since 2010 have been identified as ST62 (n = 5) and ST6521 (n = 3).
Serotype 23B was not detected in OM in Gipuzkoa until February 2011, but became the
most frequent among non-PCV13 serotypes in 2011–2013 and 2014–2016. All serotype 23B
isolates from both regions were identified as ST2372.
Vaccination status and serotypes
Taking into account all cases from both regions, the proportion of PCV13 serotypes decreased
after PCV13 introduction: from 12/17 (70.6%) episodes in 2008–2010 to 30/74 (40.5%) in
2011–2016 (p = 0.03) in vaccinated children and from 26/35 (74.3%) to 39/78 (50%) in unvac-
cinated children for the same periods (p = 0.02).
Since 2011, in vaccinated children, the proportion of PCV13 serotypes causing OM has
been higher in Gipuzkoa (23/37, 62.2%) than in Barcelona (7/37, 18.9%, p<0.001) (Table 4).
The high proportion of PCV13 serotypes in vaccinated children in Gipuzkoa is attributable to
several PCV13 serotypes, without the emergence of a particular serotype. In Gipuzkoa, since
2011, the proportion of serotype 3 OM infections was lower in vaccinated (5/37, 13.5%) than
in unvaccinated (21/55, 38.2%) children (p = 0.01).
In unvaccinated children since 2011, however, no difference in the distribution of PCV13
serotypes was observed between Gipuzkoa and Barcelona: 26/55 (47.3%) and 13/23 (56.5%),
respectively (p = 0.62). Most cases were due to serotype 3 (21/26) in Gipuzkoa and to serotypes
19F and 19A (10/13 episodes) in Barcelona.
Reinfections
Both in Gipuzkoa and in Barcelona, 3 children suffered reinfections representing 2.7% and 3.5%
of all OM cases, respectively, 3.3% and 5% considering only the post-PCV13 period (2011–2016).
All 6 reinfections were attributable to an isolate with a different serotype to that causing the first
episode, except in one patient who suffered two episodes caused by the same serotype 11A but dif-
ferent genotypes ST838 and ST6521 belonging to the same clonal complex (Table 6).
Mixed Infections
Of the 204 episodes of OM studied, 54 (26.5%) corresponded to mixed infections (Table 7). Of
them, 37 (31.9%) occurred in Gipuzkoa and 17 (19.3%) in Barcelona, with H. influenzae
Table 6. Serotypes and vaccination status of reinfection episodes.
Region Patient a First
episode
Reinfection episode Year of episode
First/reinfection
Time (days)
between episodes
Gipuzkoa 1 23B 15B 2014/2015 308
2a 3 11A 2012/2016 1177
3 19A 8 2012/2015 1000
Barcelona 1a 11A 11A 2014/2014 196
2a 11A 25F 2014/2015 76
3 23B 21 2012/2012 279
a Patients vaccinated with PCV13
https://doi.org/10.1371/journal.pone.0209048.t006
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(44/54, 81.5%) being the most frequent microorganism isolated together with S. pneumoniae.
Serotypes 3 (9/54, 16.7%), 11A (9/54, 16.7%) and 23B (6/54, 11.1%) were the most prevalent in
mixed infections. In fact, serotype 23B was more frequently found in mixed infections (6
cases) than alone (5 cases).
Discussion
At present, PCV13 is the pneumococcal conjugate vaccine in use that covers the largest num-
ber of serotypes causing invasive diseases [23]. IPD constitutes a group of severe infectious dis-
eases but there are other milder pneumococcal infections, like OM, that are also a major health
and economic burden. Several research studies have shown that PCV13 protects from pneu-
mococcal OM and from complications such as reinfections [9]. Nevertheless, the fact that not
all pneumococcal serotypes can be included in a single conjugate vaccine makes it necessary to
conduct studies determining the distribution of serotypes causing human infections.
In this study, the decision to send an ear exudate for culture when the presence of infection
was suspected was made by the treating pediatricians. In Gipuzkoa, the demand for OM diag-
nosis increased 60–70% between 2008–2010 and 2011–2013 without a plausible explanation,
as the rates of total bacterial pathogens identified by culture remained steady and no outbreaks
of any particular pathogen were observed (data not shown). Consequently, the difference in
the absolute number of S. pneumoniae isolated between periods in Gipuzkoa cannot be attrib-
utable to an increase in pneumococcal OM infections but rather to an increase in the demand
for microbiological analysis. In fact, the rate of S. pneumoniae positive cultures decreased after
the introduction of PCV13.
In Barcelona, the percentage of children with OM that had been vaccinated was 58%, simi-
lar to the figure of 55% reported for the general population [24]. Contrarily, in Gipuzkoa, the
percentage of vaccinated children with OM was 34.5%, nearly half of the 70% coverage esti-
mated for the population overall. Another difference between the two regions was the higher
prevalence of OM caused by serotype 3 in Gipuzkoa and by serotype 19A in Barcelona. It is
plausible that other factors, such as serotype prevalence or specific clones circulating at the
time of introducing PCV13, could have influenced the effect of the vaccine in each region.
In Gipuzkoa, after PCV13 introduction, the decrease in OM caused by PCV13 serotypes did
not reach statistical significance because of the persistence of serotype 3 and despite the dra-
matic decrease in serotype 19A. A similar trend for serotypes 3 (persistence) and 19A (decrease)
causing OM has been previously described by other authors [25,26]. The persistence of serotype
3 infections in Gipuzkoa was especially evident in unvaccinated children because, unlike in
other studies [27,28], a lower rate of serotype 3 OM was observed in vaccinated children.
In Barcelona, however, a very significant decrease in PCV13 serotypes was observed as seen
in preceding surveys [26], a decrease that paralleled the decrease in serotype 19A. The near dis-
appearance of serotype 19A among unvaccinated children from both regions could be due to
the herd protection effect of PCV13, an effect not observed for serotype 3 in Gipuzkoa.
Table 7. Number (percentage) of pneumococcal single and mixed OM infections in Gipuzkoa and Barcelona.
Gipuzkoa Barcelona Total
S. pneumoniae alone 79 (68.1) 71 (80.7) 150 (73.5)
S. pneumoniae and H. influenzae 21 (18.1) 16 (18.2) 37 (18.1)
S. pneumoniae and H. influenzae and other bacteria 6 (5.2) 1 (1.1%) 7 (3.4%)
S. pneumoniae and other bacteria 10 (8.6) 0 (0) 10 (4.9)
Total 116 (100) 88 (100) 204 (100)
https://doi.org/10.1371/journal.pone.0209048.t007
Pneumococcal otitis media in Spain after PCV13
PLOS ONE | https://doi.org/10.1371/journal.pone.0209048 December 18, 2018 8 / 12
The association of serotype 19F with OM and the weak protection of PCVs against OM
caused by this serotype have been described previously [11,29,30]. After PCV7 introduction in
Gipuzkoa, a large drop was observed in the prevalence serotype 19F [12]. The slight increase in
serotype 19F incidence in Gipuzkoa and Barcelona was due to ST179 isolates that proved to be
a successful clone causing OM even in PCV13-vaccinated children.
After PCV13 introduction, two similar epidemiological changes in non-PCV13 serotypes
were observed in both regions: an increase in the rate and diversity of non-PCV13 serotypes or
serotype replacement, a well described phenomenon in IPD and OM [20,24] and a sharp
increase in a different single serotype in each region. In Barcelona, in the post-vaccine period
there was a dramatic increase in OM caused by serotype 11A, ST838 and ST6521 (all penicil-
lin-resistant, data not shown). ST838 and ST6521 share six of the seven alleles differing in two
nucleotides at the aroE allele and are SLV and DLV (double-locus variant) of ST156, respec-
tively. Since 2010, a marked increase in a penicillin-resistant serotype 11A ST838/ST6521
clone has been observed among invasive Spanish isolates [31]. First detected in Spain in 2005,
ST838/ST6521 is a SLV/DLV capsular variant of the successful Spain9V-156 clone, a worldwide
disseminated penicillin-resistant clone before PCV7 introduction [31]. This finding under-
scores the need for close monitoring of not only the serotypes, but also the genotypes of all
types of pneumococcal infections over time.
In Gipuzkoa, an increase in serotype 23B ST2372 has been observed since 2011, coinciding
in time with the introduction of PCV13, and more frequently found in unvaccinated children
with mixed OM. Serotype 23B ST2372, also observed in two isolates from Barcelona, was first
found among 23B invasive isolates in the UK [32]. Surprisingly, in the UK, ST2372 was
described as a genotypic subtype of serotype 23B, with the same capsular polysaccharide struc-
ture and immune reactivity as serotype 23B but with<70% similarity to the reference 23B cap-
sular cassette sequence. In Gipuzkoa, as well as in UK, ST2372 prevalence increased after 2010.
The concurrence in time of the appearance of ST2372 in Gipuzkoa, Barcelona and UK indi-
cates a local appearance of this clone derived from isolates already present in each region.
Considering the entire post-PCV13 period, a decrease in the percentage of pneumococcal
reinfections in patients with a first pneumococcal OM, from 12.1% (1999–2010) to 3.3%
(2011–2016) was observed in Gipuzkoa [2]. It has been reported that prevention of first epi-
sodes of OM caused by vaccine serotypes reduces recurrences and chronic cases [9]. Besides,
the composition of microbiota differs greatly between PCV7-vaccinated and non-vaccinated
children [33]. Hence, changes in nasopharyngeal microbiota generated by pneumococcal vac-
cination might reduce the risk of later complex pneumococcal OM as observed in our study.
Overall, in nearly one third of pneumococcal OM a second pathogen was isolated together
with S. pneumoniae, a similar rate to previous studies [12] with H. influenzae again being the
most frequent microorganism found in mixed infections.
The results herein reported corroborate earlier observations such as the reduction in OM
caused by vaccine serotypes after PCV introduction [9], and the weak protection against sero-
types 3 and 19F OM [6,11, 26,29]. Moreover, this study shows the spread of serotype 11A caus-
ing OM in Spain as has already been described in invasive disease [31] and the spread and
association of the international serotype 23B ST2372 clone with mixed OM in Gipuzkoa. Sev-
eral differences in the epidemiology of OM between the two regions were also observed, in
particular, the higher rate of sample collection by pediatricians in Gipuzkoa; the lower rate of
vaccinated children with pneumococcal OM in Gipuzkoa; the different distribution of PCV13
serotypes, with lower serotype 3 but higher serotype 19A OM rates in Barcelona; and the dif-
ferently successful spread of serotype 11A in Barcelona and 23B in Gipuzkoa. Until a pneumo-
coccal vaccine capable of protecting against all pneumococcal serotypes becomes available, all
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these observations reflect the importance of continuous epidemiological studies to analyze the
effect of conjugate vaccines on non-invasive pneumococcal infections.
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